![](/img/cover-not-exists.png)
Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Stein, Anthony, Franklin, Janet L., Chia, Victoria M., Arrindell, Deborah, Kormany, William, Wright, Jacqueline, Parson, Mandy, Amouzadeh, Hamid R., Choudhry, Jessica, Joseph, GuiandreLanguage:
english
Journal:
Drug Safety
DOI:
10.1007/s40264-018-0760-1
Date:
December, 2018
File:
PDF, 1.23 MB
english, 2018